Vaccine hope jumps on a dose of Moderna COVID-19 vaccine news
Head of Equity Strategy
Summary: Moderna shares were up 20% on the news that its COVID-19 vaccine shows promising results of immune system response and generally good safety in its phase 1 study. However, investors should be a bit cautious putting too much weight on the news as the study only consisted of 45 subjects and phase 1 studies are dominated by false positives.
Moderna, a US-based biotechnology company, which is on the official WHO list of companies working on a COVID-19 vaccine and highlighted in our research note from 7 May on companies working on vaccines. Yesterday, the company published interim phase 1 trial on their SARS-CoV-2 vaccine showing the vaccine was generally safe and well tolerated. Shares rose 20% and the news helped sentiment in global equities to improve further.
But some important points around the Moderna study is worth reflecting on. The phase 1 trial design consisted of 45 subjects placed in three cohorts of dose level. This is a small sample size and thus investors should not put too much weight on these finding for now. Phase 2 study will begin shortly and consist of 600 subjects and thus provide a better sample size before moving to the real test in phase 3. Investors should recognize that the false positives far exceeds the number of true positives in drug discovery and especially in phase 1 studies. Randomness exists everywhere and also in drug discovery. The dividend futures market price a bit steeper curve (more positive growth outlook) but not by much so in essence not putting that much weight on Moderna’s news.
After the initial release of the phase 1 study data Moderna announced a public offering of shares worth $1.3bn at $76 per share indicating that the company is taking advantage of its market value to raise additional capital fund research and development. This will likely be the environment going forward that biotechnology companies will release data on COVID-19 and spin it positively to get more funding and potentially access to partnership funding from large pharmaceuticals and governments.
Latest Market Insights
Outrageous Predictions 2023: The War Economy
- The constantly growing global need for energy drives the world's richest to huddle up and launch a R&D project in a size the world hasn't seen since the Manhattan Project gave the US the first atomic bomb.
French President Macron resignsThe political stalemate in France and the rise of Marie Le Pen following the 2022 elections corners President Macron, forcing him to give up on politics and resign from his position. At least for now.
Gold rockets to USD 3,000 as central banks fail on inflation mandateAs markets and central banks realise that the idea that inflation is transitory is wrong, and that prices will remain higher for longer, gold is sent through the roof, hitting a price tag of USD 3,000
EU Army forces EU down path to full unionWith continued challenges in the region and a US military that isn't aggressively enacting its former role as global policeman, the European Union agrees to create its own armed forces, bringing the whole region closer.
A country agrees to ban all meat production by 2030In an effort to become one of the global leaders on the path to net-zero emissions, one country decides to not only put a heavy tax on meat, but to ban domestic production entirely.
UK holds UnBrexit referendumFollowing a recession and domestic pressure, the United Kingdom is thrown into political turmoil that will end with a vote to wind back Brexit.
Widespread price controls are introduced to cap official inflationHistory tells us that with the war economy comes rationing and price controls. And this time is no different, as policymakers introduce strict price controls that lead to a range of unintended consequences.
OPEC+ & Chindia walk out of the IMF, agree to trade with new reserve assetSanctions against Russia have caused widespread turmoil due to US Dollar moves in countries across the globe that don't consider the US an ally. To relieve themselves from this, they leave the IMF and create a new reserve asset.
USDJPY fixed to the USD at 200 as Japan overhauls financial systemFollowing the challenges that faced the Japanese Yen in 2022, the Bank of Japan attempts to keep the currency from sliding. Unsuccessful on the long-term, Japan will launch a reset of its entire financial system.
Tax haven ban kills private equityWith the war economy comes an increased focus on national interests and sovereign nations' ability to assert themselves. In that regard, the OECD countries turn their attention on tax havens and pull the big guns out, banning them altogether.